Search results
Showing 1651 to 1665 of 8910 results
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)
Evidence-based recommendations on pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer in adults.
Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes in adults.
Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults.
Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)
Evidence-based recommendations on peginterferon beta-1a (Plegridy) for treating relapsing–remitting multiple sclerosis in adults.
Evidence-based recommendations on anakinra (Kineret) for treating adult-onset Still’s disease and systemic juvenile idiopathic arthritis in people 8 months and older.
Evidence-based recommendations on nivolumab (Opdivo) as a possible treatment for completely resected oesophageal or gastro-oesophageal junction cancer in adults.
Awaiting development Reference number: GID-TA10393 Expected publication date: TBC
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]
In development Reference number: GID-TA10497 Expected publication date: TBC
In development Reference number: GID-TA10542 Expected publication date: TBC
Gosuranemab for treating progressive supranuclear palsy [ID1607]
Awaiting development Reference number: GID-TA10553 Expected publication date: TBC
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]
In development Reference number: GID-TA10573 Expected publication date: TBC
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]
Awaiting development Reference number: GID-TA10604 Expected publication date: TBC
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]
Awaiting development Reference number: GID-TA10431 Expected publication date: TBC
Awaiting development Reference number: GID-TA10439 Expected publication date: TBC
In development Reference number: GID-TA10446 Expected publication date: TBC